10-Q: Moleculin Biotech Q2: Nasdaq Woes Amidst Annamycin Progress

Moleculin Biotech reported a widened net loss in Q2 2025, facing Nasdaq delisting concerns, while advancing its lead drug Annamycin into a pivotal Phase 3 trial with promising preclinical data and patent grants.

Summary

• Net loss for the three months ended June 30, 2025, widened to $7.64 million, compared to $4.32 million for the same period in 2024.
• For the six months ended June 30, 2025, net loss was $14.08 million, up from $9.29 million in the prior year period.
• Research and development (R&D) expenses decreased by $0.5 million to $3.6 million for Q2 2025 and by $1.3 million to $7.04 million for the six months ended June 30, 2025, primarily due to reduced clinical trial activity.
• General and administrative (G&A) expenses remained stable at approximately $2.1 million for Q2 2025 and increased slightly by $0.1 million to $4.57 million for the six months ended June 30, 2025.
• Cash and cash equivalents increased to $7.56 million as of June 30, 2025, from $4.28 million at December 31, 2024, driven by financing activities.
• Total liabilities significantly increased to $28.76 million at June 30, 2025, from $10.95 million at December 31, 2024, largely due to an increase in warrant liability.
• Stockholders' equity shifted to a deficit of $7.17 million at June 30, 2025, from a positive equity of $5.98 million at December 31, 2024.
• A significant gain from change in fair value of warrant liability of $9.61 million was recorded in Q2 2025 ($18.66 million for six months), while losses on issuance of warrant liabilities totaled $10.35 million in Q2 2025 ($18.15 million for six months).
• The company is not in compliance with Nasdaq's minimum stockholders' equity rule ($2.5 million) and minimum bid price rule ($1.00 per share), facing potential delisting.
• The pivotal Phase 3 MIRACLE trial for Annamycin in relapsed/refractory AML is underway, with 8 subjects treated as of July 25, 2025, and interim data unblinding expected by end of 2025.
• Annamycin has demonstrated no evidence of drug-related cardiotoxicity in 84 subjects across five clinical trials, including doses significantly exceeding FDA lifetime maximums for other anthracyclines.
• New patents for Annamycin have been granted or are pending in the US and EU, extending exclusivity into 2040, and the WHO approved 'naxtarubicin' as its non-proprietary name.

Sentiment

Score: 3

Explanation: The company faces severe financial distress with negative stockholders' equity and immediate Nasdaq delisting threats. While clinical progress with Annamycin and patent grants are positive, the significant liquidity concerns and reliance on highly dilutive financing overshadow these developments, indicating a very high-risk investment profile.

Positives

• Annamycin's pivotal Phase 3 MIRACLE trial for relapsed/refractory AML is actively recruiting and treating subjects, with interim data unblinding expected by the end of 2025.
• Annamycin has shown no evidence of drug-related cardiotoxicity in 84 subjects across five clinical trials, even at doses significantly above FDA lifetime maximums for other anthracyclines, addressing a major limitation of current anthracyclines.
• Positive FDA feedback was received for a single pediatric approval study for Annamycin in children with relapsed/refractory AML, with the trial expected to commence in the second half of 2027.
• The completed MB-107 trial for Annamycin monotherapy in STS Lung Mets demonstrated a median overall survival of 13.5 months for subjects as median 7th line therapy, comparing favorably to standard of care (8-12 months) and experimental treatments (13.4 months) as 2nd line.
• Multiple new patents for Annamycin have been granted or are in the process of being granted in the US and EU, extending intellectual property protection until 2040.
• The World Health Organization (WHO) approved 'naxtarubicin' as the International Non-Proprietary Name (INN) for Annamycin, establishing a universally recognized name.
• Net cash used in operating activities decreased to $10.15 million for the six months ended June 30, 2025, from $12.67 million in the prior year period, indicating a reduction in operational cash burn.

Negatives

• The company reported a significant net loss of $7.64 million for Q2 2025 and $14.08 million for the six months ended June 30, 2025, indicating continued unprofitability.
• Stockholders' equity has fallen into a deficit of $7.17 million as of June 30, 2025, from a positive equity of $5.98 million at December 31, 2024, primarily due to losses and warrant accounting.
• The company is not in compliance with Nasdaq's Listing Rule 5550(b)(1) requiring a minimum of $2.5 million in stockholders' equity.
• The company is not in compliance with Nasdaq's Listing Rule 5550(a)(2) requiring a minimum bid price of $1.00 per share, with the stock closing below this threshold for 30 consecutive business days.
• There is a substantial risk of delisting from Nasdaq if compliance is not regained by December 24, 2025, or subsequent extended periods.
• The accounting for Series E warrants as a liability resulted in a $10.35 million loss on issuance in Q2 2025 ($18.15 million for six months) and negatively impacts stockholders' equity.
• Current cash on hand of $7.56 million is only sufficient to fund planned operations into the fourth quarter of 2025, necessitating additional financing.
• The company requires approximately $10 million in additional funding to support the MIRACLE trial and operations into the first quarter of 2026.

Risks

• Inability to regain compliance with Nasdaq's minimum stockholders' equity and minimum bid price requirements, leading to potential delisting of common stock.
• Delisting from Nasdaq could severely impact the ability to raise additional financing, reduce liquidity and value of common stock, and deter institutional investors.
• Future capital raises, especially through equity offerings, may result in significant dilution to existing shareholders, particularly due to the 'Down Round Feature' of Series E warrants which can reduce exercise price and increase shares issuable.
• The ongoing SEC subpoena and investigation, initiated in March 2022, could result in unforeseen actions or penalties, despite the company's belief in the accuracy of prior disclosures.
• Clinical trials, including the pivotal Phase 3 MIRACLE trial, are subject to risks such as recruitment challenges, regulatory hurdles, and potential safety issues that could lead to clinical holds or trial failures.
• The company's reliance on third-party manufacturers for drug supplies and third-party collaborators for marketing and distribution introduces dependency risks.
• The potential for future cardiac events in Annamycin trials, despite current data showing no cardiotoxicity, could be difficult to disassociate from the drug and impact regulatory approval or market acceptance.
• Maintaining and protecting intellectual property rights is crucial, and any challenges to patents could adversely affect the company's competitive position.

Future Outlook

The company expects interim unblinding of data from its pivotal Phase 3 MIRACLE trial for Annamycin by the end of 2025, with an additional unblinding in the first half of 2026. A pediatric trial for Annamycin in children with R/R AML is expected to commence in the second half of 2027. Results from preclinical studies of WP1066 IV formulations at Emory University are anticipated in the second half of 2025. The company intends to monitor its common stock bid price and may consider a reverse stock split to regain Nasdaq compliance. Additional funding of approximately $10 million is required to support the MIRACLE trial and operations into the first quarter of 2026.

Management Comments

• "We believe such early visibility for a pivotal registration-enabling trial is highly unique in that stakeholders will receive preliminary safety and efficacy data in the MIRACLE trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) within one year of dosing the first subject."
• "We believe that the potential for such future incidences, however, does not outweigh the significant lack of cardiotoxicity to date as reflected in the Experts reports."
• "We intend to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split."
• "We believe that our cash on hand and cash equivalents as of June 30, 2025, is sufficient to fund our planned operations into the fourth quarter of 2025."
• "We must seek additional funding of approximately $10 million to support MIRACLE and our operations into the first quarter of 2026 through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof to continue our operations in the near term."

Industry Context

The company operates in the highly capital-intensive and risky clinical-stage pharmaceutical development sector, focusing on hard-to-treat cancers like AML, STS, and glioblastoma. Its lead drug, Annamycin, is an anthracycline, a class of chemotherapy often limited by cardiotoxicity. The company's focus on developing a non-cardiotoxic anthracycline could be disruptive to the competitive landscape if successful, as heart damage is a significant concern for cancer patients treated with existing anthracyclines. The reliance on investigator-initiated trials for other drug candidates is a common strategy for smaller biotech firms to conserve capital while advancing their pipeline.

Comparison to Industry Standards

• Annamycin's demonstrated lack of cardiotoxicity in 84 subjects across five clinical trials, including doses significantly beyond FDA lifetime maximums for currently prescribed anthracyclines, stands in stark contrast to the known cardiotoxic effects of other anthracyclines, where studies show the incidence of heart failure more than doubles for treated cancer patients (C Larson, et al. JAMA Network Open. 2023;6(2):e2254669).
• The median overall survival (OS) of 13.5 months for Annamycin monotherapy in the MB-107 trial for STS Lung Mets (as median 7th line therapy, n=36) compares favorably to reported OS of 8-12 months for standard of care treatments and 13.4 months for experimental treatments for advanced STS as 2nd line (Comandone A, et al; The Oncologist 2017;22:15181527), suggesting potential efficacy even in heavily pre-treated patients.

Corporate Governance

Legal Proceedings

• The company received a subpoena from the SEC in March 2022 requesting information and documents related to certain individuals and entities, and materials related to the development of and statements regarding its drug candidate for the treatment of COVID-19. The investigation is ongoing, and the company cannot predict its resolution or any potential SEC actions.

Related Party Transactions

• The company sublicensed its technologies to Animal Life Sciences, Inc. (ALI) in 2019, receiving a 10% equity interest in ALI.
• The company recorded approximately $12,000 in sublease income from a related party for the three months ended June 30, 2025 and 2024, and $25,000 and $24,000 for the six months ended June 30, 2025 and 2024, respectively.
• Expenses related to agreements with Houston Pharmaceuticals, Inc. (HPI), a related party, were $59,000 for each of the three months ended June 30, 2025 and 2024, and $117,000 for each of the six months ended June 30, 2025 and 2024, respectively.
• Accounts payable includes $20,000 as of June 30, 2025 and December 31, 2024, respectively, for related party payables.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises, potential loss of investment value due to Nasdaq delisting, and uncertainty regarding the company's ability to continue as a going concern. However, successful clinical trial outcomes could provide substantial upside.
• **Employees**: Potential impact on morale and retention due to financial instability and delisting concerns, though clinical progress may offer some stability.
• **Customers/Patients**: Potential benefit from new treatment options for hard-to-treat cancers if Annamycin and other drug candidates achieve regulatory approval and commercialization.
• **Suppliers/Creditors**: Increased risk due to the company's accumulated deficit, negative stockholders' equity, and stated need for additional financing to fund operations.
• **Regulatory Authorities (FDA, EMA, Nasdaq)**: Continued engagement with regulatory bodies for clinical trial approvals and compliance, and with Nasdaq regarding listing requirements.

Next Steps

• Seek warrant stockholder approval and authorized share approval at the Annual Meeting on August 18, 2025, and potentially subsequent meetings every 60 days until approval is obtained.
• Monitor common stock bid price and consider options, including a reverse stock split, to regain Nasdaq compliance by December 24, 2025.
• Continue recruitment and treatment of subjects in the pivotal Phase 3 MIRACLE trial for Annamycin.
• Anticipate interim unblinding of MIRACLE trial data by the end of 2025 and additional unblinding in the first half of 2026.
• Proceed with the MIRACLE trial in the US, as amended, following FDA feedback.
• Commence the single pediatric approval study for Annamycin in children with R/R AML in the second half of 2027.
• Await results from WP1066 IV preclinical studies at Emory University, expected in the second half of 2025.
• Negotiate further sponsored research agreements with various parties.
• Seek additional funding of approximately $10 million through equity offerings, debt financings, or strategic partnerships to fund operations into the first quarter of 2026.

Key Dates

Recommendation

The company faces immediate and severe financial challenges, including a negative stockholders' equity, a widening net loss, and explicit non-compliance with two critical Nasdaq listing rules, which puts it at high risk of delisting. While there is promising clinical progress with Annamycin and new patent grants, these positive developments are overshadowed by the urgent need for substantial additional financing, which will likely come through highly dilutive equity offerings. The 'Down Round Feature' of the Series E warrants further exacerbates the dilution risk. The combination of severe financial distress, imminent delisting threat, and reliance on dilutive capital raises makes the stock a high-risk proposition with significant downside potential in the near to medium term, despite long-term clinical prospects.

Keywords

Moleculin Biotech, MBRX, Annamycin, naxtarubicin, AML, Acute Myeloid Leukemia, Soft Tissue Sarcoma, STS, Glioblastoma, Oncology, Biotech, Pharmaceutical, Clinical Trial, Phase 3, Nasdaq, SEC, Warrant Liability, Capital Raise, Cardiotoxicity, Patent